
ROIV Stock Forecast & Price Target
ROIV Analyst Ratings
Bulls say
Roivant Sciences Ltd's product brepocitinib (brepo) is positioned to capture a significant market opportunity, offering a convenient once-daily dosing regimen that stands in contrast to the cumbersome intravenous immunoglobulin (IVIg) therapy, which has approximately $500 million in global sales. Brepo's clinical trials underscore its efficacy, demonstrated by a mean total improvement score (TIS) of 46.5, indicating a substantial therapeutic benefit that meets high expectations from investors and key opinion leaders. The strong performance of brepo and its potential market application enhances Roivant Sciences's overall growth prospects, contributing to a positive outlook for the company's stock.
Bears say
Roivant Sciences Ltd has experienced significant setbacks in its clinical development portfolio, particularly with the failure of key assets such as IMVT and brepocitinib in various therapeutic areas. These failures raise concerns about the company's ability to successfully advance its drug candidates, potentially jeopardizing future revenue streams. Consequently, the frequent clinical trial failures indicate a challenging path ahead, which could negatively impact investor confidence and overall market performance.
This aggregate rating is based on analysts' research of Roivant Sciences Ltd and is not a guaranteed prediction by Public.com or investment advice.
ROIV Analyst Forecast & Price Prediction
Start investing in ROIV
Order type
Buy in
Order amount
Est. shares
0 shares